OKYO יחס מהיר OKYO Pharma Ltd

OKYO Pharma Limited (OKYO) currently lacks pricing power as its developments have not yet reached the market, although successful trials could shift this dynamic. High certification costs and delivery patents create significant barriers to entry for new players. Share price volatility, indicated by 2.54, reflects typical biotech price action. The business focuses on developing dry eye treatments, ensuring stable demand and long-term profitability.

The quick ratio measures a business's ability to meet immediate obligations using only cash and accounts receivable, excluding illiquid inventory. By analyzing this quick ratio chart, an investor assesses the financial autonomy of OKYO Pharma Limited, whose ophthalmological developments in the US and UK are protected by humanitarian status and minimal geopolitical risks.